Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: A case-control study

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 2, 2014, Pages 229-238.e3

  Garcia, Jose M ^a,b   Splenser, Andres E ^a,b   Kramer, Jennifer ^b,c   Alsarraj, Abeer ^b,c   Fitzgerald, Stephanie ^b,c   Ramsey, David ^b,c   El Serag, Hashem B ^a,b,c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adipokines; Adiponectin; GERD; Insulin; Leptin; NSAID; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; GAMMA INTERFERON; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CASE CONTROL STUDY; COLONOSCOPY; CONTROLLED STUDY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGOSCOPY; FEMALE; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIMARY MEDICAL CARE; RISK ASSESSMENT; RISK FACTOR; SCREENING;

ADIPOKINES; ADIPONECTIN; BARRETT'S ESOPHAGUS; BE; BMI; BODY MASS INDEX; CI; CONFIDENCE INTERVAL; EGD; ESOPHAGOGASTRODUODENOSCOPY; GASTROESOPHAGEAL REFLUX DISEASE; GERD; H2RA; HISTAMINE 2 RECEPTOR ANTAGONIST; IFN; IL; INSULIN; INTERFERON; INTERLEUKIN; JNK; JUN N-TERMINAL PROTEIN KINASE; LEPTIN; MEDVAMC; MICHAEL E. DEBAKEY VA MEDICAL CENTER; NONSTEROIDAL ANTI-INFLAMMATORY DRUG; NSAID; OBESITY; ODDS RATIO; OR; PCP; PPI; PRIMARY CARE PROVIDER; PROTON PUMP INHIBITOR; TNF; TUMOR NECROSIS FACTOR; W/H; WAIST/HIP;

ADIPOKINES; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INTERLEUKINS; LEPTIN; MALE; MIDDLE AGED; OBESITY; RISK ASSESSMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892479321     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.038     Document Type: Article

References (51)

1. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. JNatl Cancer Inst 2005, 97:142-146.
2. Brown L.M., Devesa S.S. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002, 11:235-256.
3. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 2003, 27:999-1008. discussion 6-8.
4. Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005, 143:199-211.
5. Cook M.B., Greenwood D.C., Hardie L.J., et al. Asystematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008, 103:292-300.
6. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007, 133:34-41. quiz 311.
7. El-Serag H.B., Kvapil P., Hacken-Bitar J., et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005, 100:2151-2156.
8. Singh S., Sharma A.N., Murad M.H., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:1399-1412.
9. Duggan C., Onstad L., Hardikar S., et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013, 11:934-943.
10. Quante M., Bhagat G., Abrams J.A., et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012, 21:36-51.
11. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
12. Kubota N., Yano W., Kubota T., et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007, 6:55-68.
13. Schwartz M.W., Porte D. Diabetes, obesity, and the brain. Science 2005, 307:375-379.
14. Morton G.J. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. JPhysiol 2007, 583(Pt 2):437-443.
15. Beales I.L., Ogunwobi O.O. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 2007, 274:60-68.
16. Ogunwobi O.O., Beales I.L. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor. Br J Biomed Sci 2008, 65:121-127.
17. Engineer D.R., Garcia J.M. Leptin in anorexia and cachexia syndrome. Int J Pept 2012, 2012:287457.
18. Zhang H.Y., Zhang Q., Zhang X., et al. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2011, 300:G454-G460.
19. Kelesidis I., Kelesidis T., Mantzoros C.S. Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94:1221-1225.
20. Rubenstein J.H., Dahlkemper A., Kao J.Y., et al. Apilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 2008, 103:1358-1364.
21. Kendall B.J., Macdonald G.A., Hayward N.K., et al. Leptin and the risk of Barrett's oesophagus. Gut 2008, 57:448-454.
22. Greer K.B., Thompson C.L., Brenner L., et al. Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut 2012, 61:665-672.
23. Agarwal R., Jin Z., Yang J., et al. Epigenomic program of Barrett's-associated neoplastic progression reveals possible involvement of insulin signaling pathways. Endocr Relat Cancer 2012, 19:L5-L9.
24. Locke G.R., Talley N.J., Weaver A.L., et al. Anew questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994, 69:539-547.
25. Locke G.R., Talley N.J., Fett S.L., et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
26. Sharma P., McQuaid K., Dent J., et al. Acritical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004, 127:310-330.
27. Kramer F.L., Richardson R., Alsarraj A., et al. Waist to hip ratio but not body mass index is associated with increased risk of Barrett's esophagus in white men. Clin Gastronterol Hepatol 2013, 11:373-381.
28. El-Serag H.B., Hashmi A., Garcia J., et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut 2013, Feb 13. Epub ahead of print.
29. El-Serag H. Role of obesity in GORD-related disorders. Gut 2008, 57:281-284.
30. Cannon J.G., Nerad J.L., Poutsiaka D.D., et al. Measuring circulating cytokines. JAppl Physiol 1993, 75:1897-1902.
31. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. JClin Invest 2003, 112:1821-1830.
32. Omer Z.B., Ananthakrishnan A.N., Nattinger K.J., et al. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012, 10:722-727.
33. Moons L.M., Kusters J.G., van Delft J.H., et al. Apro-inflammatory genotype predisposes to Barrett's esophagus. Carcinogenesis 2008, 29:926-931.
34. Gough M.D., Ackroyd R., Majeed A.W., et al. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important?. Am J Gastroenterol 2005, 100:1012-1018.
35. Kohata Y., Fujiwara Y., Machida H., et al. Role of Th-2 cytokines in the development of Barrett's esophagus in rats. JGastroenterol 2011, 46:883-893.
36. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002, 51:316-322.
37. Matsuki T., Horai R., Sudo K., et al. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. JExp Med 2003, 198:877-888.
38. El-Omar E.M. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut 2001, 48:743-747.
39. Tselepis C., Perry I., Dawson C., et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002, 21:6071-6081.
40. Zhong Y.Q., Lin Y., Xu Z. Expression of IFN-gamma and IL-4 in the esophageal mucosa of patients with reflux esophagitis and Barrett's esophagus and their relationship with endoscopic and histologic grading. Dig Dis Sci 2011, 56:2865-2870.
41. Thompson O.M., Beresford S.A., Kirk E.A., et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 2010, 18:2204-2211.
42. Wang Y., Kuropatwinski K.K., White D.W., et al. Leptin receptor action in hepatic cells. JBiol Chem 1997, 272:16216-16223.
43. Lee G.H., Proenca R., Montez J.M., et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996, 379:632-635.
44. Wisse B.E., Ogimoto K., Morton G.J., et al. Physiological regulation of hypothalamic IL-1beta gene expression by leptin and glucocorticoids: implications for energy homeostasis. Am J Physiol Endocrinol Metab 2004, 287:E1107-E1113.
45. Maeda K., Okubo K., Shimomura I., et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
46. Chandran M., Phillips S.A., Ciaraldi T., et al. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003, 26:2442-2450.
47. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
48. Matsuzawa Y., Funahashi T., Kihara S., et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24:29-33.
49. Stefan N., Vozarova B., Funahashi T., et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888.
50. Konturek P.C., Burnat G., Rau T., et al. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 2008, 53:597-605.
51. Rubenstein J.H., Kao J.Y., Madanick R.D., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut 2009, 58:1583-1589.